TREATMENT
Intensive glucose control did not prevent important complications in type 2 diabetes
| The first 150 words of the full text of this article appear below. |
A Patel
Dr A Patel, University of Sydney, Sydney, New South Wales, Australia; apatel@george.org.au
In type 2 diabetes, does intensive glucose control prevent adverse outcomes more than standard glucose control?
Design: randomised controlled trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]).
Allocation: concealed.
Blinding: blinded (outcome adjudication committee).
Follow-up period: median 5 years.
Setting: 215 centres in 20 countries worldwide.
Patients:
11 140 patients 
55 years of age (mean age 66 y, 58% men) who had type 2 diabetes and a history of, or risk factors for, vascular disease. Patients requiring insulin were excluded.
Intervention:
intensive glucose control with gliclazide, modified-release, 30–120 mg/day, and other non-sulfonylurea drugs as needed to achieve a target glycated haemoglobin (HbA1c) concentration 
6.5% (n = 5571) or standard glucose control with drugs other than gliclazide (n = 5569).
Outcomes:
composite of major macrovascular events (non-fatal myocardial infarction
School of Nursing, McMaster University, Hamilton, Ontario, Canada
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
